Pancreatic Cancer Research

ResearcherMashhad University of Medical SciencesActive in the last 2 years

Majid Khazaei

ORCID-verified (high confidence, 0.95), identity_conf@1As of 6 November 2026

Matched on ORCID iD 0000-0002-7979-5699; OpenAlex author ID A5002434919. Sources: OpenAlex.

Their work

Papers
12 (first author 1, last author 1)
Trials
0
Grants
0
Labs led
0
Collaborators
18
Papers, trials and grants by year

2017: 2 papers · 2018: none · 2019: 1 paper · 2020: none · 2021: 2 papers · 2022: 2 papers · 2023: 2 papers · 2024: 2 papers · 2025: 1 paper

Papers 12

  1. Recent advances of circulating biomarkers with potential diagnostic, prognostic, and therapeutic value in pancreatic cancer: Limitations of clinical applicatio… Co-author DOI 10.1016/j.prp.2025.156045↗
  2. The circadian clock as a potential biomarker and therapeutic target in pancreatic cancer. Co-author DOI 10.1007/s11010-023-04790-4↗
  3. Microbiome as a biomarker and therapeutic target in pancreatic cancer. Co-author DOI 10.1186/s12866-023-03166-4↗
  4. Down regulation of Cathepsin W is associated with poor prognosis in pancreatic cancer. Co-author DOI 10.1038/s41598-023-42928-y↗
  5. Therapeutic Potential of Targeting Transforming Growth Factor-beta (TGF-β) and Programmed Death-ligand 1 (PD-L1) in Pancreatic Cancer. Last author DOI 10.2174/0113894501264450231129042256↗
  6. Angiotensin-converting Enzyme Inhibitors and Angiotensin Receptor Blockers as Potential Therapeutic Options for Pancreatic Cancer. Co-author DOI 10.2174/1568009622666220517104411↗
  7. Association of a Genetic Variant in the Cyclin-Dependent Kinase Inhibitor 2B with Risk of Pancreatic Cancer. Co-author DOI 10.52547/rbmb.11.2.336↗
  8. The therapeutic potential of renin-angiotensin system inhibitors in the treatment of pancreatic cancer. Co-author DOI 10.1016/j.lfs.2021.119118↗
  9. PNU-74654 enhanced the antiproliferative activity of gemcitabine via targeting Wnt/β-catenin Pathway in Pancreatic cancer Co-author DOI 10.21203/rs.3.rs-881431/v1↗
  10. Therapeutic potential of targeting the Wnt/β-catenin pathway in the treatment of pancreatic cancer. Co-author DOI 10.1002/jcb.27835↗
  11. Therapeutic Potential of Curcumin in Treatment of Pancreatic Cancer: Current Status and Future Perspectives. Co-author DOI 10.1002/jcb.25897↗
  12. Targeting stroma in pancreatic cancer: Promises and failures of targeted therapies. First author DOI 10.1002/jcp.25798↗

Closest collaborators

The 18 strongest of 18 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Gordon A. Ferns · 8 shared papers, 2019–2024 · strength 1.15
  2. Amir Avan · 5 shared papers, 2022–2025 · strength 0.91
  3. Amir Avan · 7 shared papers, 2017–2024 · strength 0.82
  4. Ghazaleh Pourali · 4 shared papers, 2023–2024 · strength 0.70
  5. Majid Ghayour‐Mobarhan · 3 shared papers, 2017–2024 · strength 0.40
  6. Zahra Yousefli · 2 shared papers, 2023–2025 · strength 0.37
  7. Fatemeh Khojasteh‐Leylakoohi · 2 shared papers, 2022–2023 · strength 0.27
  8. Fereshteh Asgharzadeh · 1 shared paper, 2022 · strength 0.17
  9. Mina Maftouh · 2 shared papers, 2017 · strength 0.15
  10. Alfred King-yin Lam · 1 shared paper, 2023 · strength 0.14
  11. Elisa Giovannetti · 1 shared paper, 2023 · strength 0.14
  12. Negar Khoshghamat · 1 shared paper, 2021 · strength 0.13
  13. Newsha Sardarzade · 1 shared paper, 2022 · strength 0.13
  14. Mohsen Aliakbarian · 1 shared paper, 2022 · strength 0.13
  15. Sajjad Sharifi · 1 shared paper, 2021 · strength 0.12
  16. Seyed Alireza Javadinia · 1 shared paper, 2019 · strength 0.09
  17. Afsane Bahrami · 1 shared paper, 2017 · strength 0.08
  18. Mina Hosseini · 1 shared paper, 2017 · strength 0.07

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.